ArticleDrug design, development and therapy2016
Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.
Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 117 citations in OpenAlex.
- Dacarbazine as a Positive Control in Melanoma Cell Lines (A375, SK-MEL-103, 1205Lu) and a Human Ex Vivo Skin Model.Advanced biology · 2026Article
- Recent advances in oncolytic virus combined immunotherapy in tumor treatment.Genes & diseases · 2025Review
- Construction and application of adenoviral vectors.Molecular therapy. Nucleic acids · 2023Review
- NLRP3 and cancer: Pathogenesis and therapeutic opportunities.Pharmacology & therapeutics · 2023Review
- Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations.Biomedicines · 2022Review
- Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.Cancer gene therapy · 2022Review
- Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.Signal transduction and targeted therapy · 2022Review
- Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal.Cancer reports (Hoboken, N.J.) · 2022Article
- Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with skin cutaneous melanoma.Frontiers in genetics · 2022Article
- Review
- Interleukin-18 Is a Prognostic Marker and Plays a Tumor Suppressive Role in Colon Cancer.Disease markers · 2020Article
- Interleukin-18 Is a Prognostic Biomarker Correlated with CD8Journal of clinical medicine · 2019Article
- Review
- Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors.Molecular therapy oncolytics · 2019Review
- Synthetically modified methoxsalen for enhanced cytotoxicity in light and dark reactions.Bioorganic & medicinal chemistry letters · 2019Article
- Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors.Frontiers in oncology · 2019Review
- CAR T cells targeting αAdvances in cell and gene therapy · 2018Article
- Deficiency of IL-18 Aggravates Esophageal Carcinoma Through Inhibiting IFN-γ Production by CD8Inflammation · 2018Article
- Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer.Frontiers in oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conditionally replicating adenoviruses have emerged as novel therapeutic agents for cancer. This study aimed to evaluate synergistic antitumor activity of replication-competent adenovirus armed with interleukin (IL)-18 (ZD55-IL-18) and dacarbazine (DTIC) against melanoma. Melanoma A375 cells or nude mouse tumor xenografts were treated with ZD55-IL-18 alone or together with DTIC. The results showed that ZD55-IL-18 competently replicated in A375 cells and expressed IL-18, and these were not affected by DTIC. ZD55-IL-18 enhanced the cytotoxicity of DTIC accompanied by increased apoptosis. Moreover, ZD55-IL-18 and DTIC synergistically inhibited the growth but promoted the apoptosis of A375 xenografts and inhibited vascular endothelial growth factor expression and lung metastasis in xenografts of nude mice. In conclusion, this is the first study to show synergistic anticancer activity of ZD55-IL-18 and DTIC for malignant melanoma. Our results provide evidence that chemo-gene-viro therapeutic approach has greater potential for malignant cancers than conventional chemotherapy or gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.